Efgartigimod Alfa shortage — IT supply status & alternatives

Efgartigimod Alfa

—

In supply · Australia

Vyvgart

In supply · 🇦🇺 Australia · short in🇮🇹 IT🇧🇪 BE

In supply in Australia

Reading today’s signals…

✓ Can I substitute?

Per normal rules

Confirm with prescriber

⇄ Best alternative

None listed

refer to prescriber

◷ Expected back

No estimate

No estimate provided

Product attributes reference data we hold

Active ingredient (INN)	Efgartigimod Alfa
Brand names	Vyvgart
Therapeutic category	Auto-created by Federal Agency for Medicines and Health Products — PharmaStatus scraper

Controlled substance	No

Patient information leaflet (PIL)	Not on file

Summary of product characteristics (SPC)	Not on file

Trade price 🇦🇺 Australia · awaiting price ingest

🇦🇺 AU

Ex-manufacturer

—

Dispensed (DPMQ)

—

Pack

—

Not yet captured for Australia

Official pricing isn’t on file for this market yet. PBS (Australia), NHS Drug Tariff (United Kingdom) and CMS NADAC (United States) feeds are prioritised; this panel populates automatically once the data lands.

Substitution pathways 🇦🇺 Australia · TGA

—

No substitution instrument in force

Dispense per normal rules, or refer to the prescriber. No active SSSI/S19A instrument detected for this medicine.

FDA-approved products 🇺🇸 Drugs@FDA

Approved applications

Generic (ANDA)

Brand (NDA/BLA)

Aug 2024

Latest approval

Shortage status by regulator official notices

🇮🇹

Italy

AIFA · 1d ago

Critical

🇧🇪

FAMHP · 9d ago

High

Verified timeline regulator events

🇮🇹 16 June 2026

critical reported

🇧🇪 16 June 2026

high reported

Sources official regulators

🇮🇹

AIFA

verified 1d ago

verify ↗

🇧🇪

FAMHP

verified 9d ago

verify ↗

Mederti Drug Report

Generated 1 July 2026 · Australia market · 2 regulatory sources

For health-professional reference only. Mederti aggregates shortage and substitution information from official regulatory sources. It is not clinical advice and data may be incomplete or delayed. Confirm any substitution or supply decision against the primary regulator source, the prescriber, and current clinical references (e.g. AMH) before acting. Terms.